Leerink Partners downgraded Carbylan Therapeutics (NASDAQ: CBYL) from Outperform to Market Perform with a price target of $1.80 (from $15.00).Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE